World’s most expensive drug approved to treat hemophilia at USD 3.5m a dose
Despite the high cost, one analyst thinks that CSL Behring’s Hemgenix, the drug that frees up patients from almost all previously needed infusions, could be successful.
By Michelle Fay Cortez, bloomberg
US regulators approved CSL Behring’s hemophilia B gene therapy, a one-off infusion that frees patients from regular treatments but costs USD 3.5m a dose, making it the most expensive medicine in the world.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.